AtriCure (ATRC) Reports In-Line Q2 EPS, provides guidance

AtriCure (NASDAQ: ATRC) reported Q2 EPS of ($0.17), in-line with the analyst estimate of ($0.17). Revenue for the quarter came in at $116.3 million versus the consensus estimate of $116.18 million.

GUIDANCE:

AtriCure sees FY2024 EPS of ($0.74)-($0.82), versus the consensus of ($0.77). AtriCure sees FY2024 revenue of $456-461 million, versus the consensus of $461.9 million.

For earnings history and earnings-related data on AtriCure (ATRC) click here.

You May Also Be Interested In

• Saudi Arabia cut the price of its main crude grade for customers in Asia in August - Bloomberg
• UBS Reiterates Buy Rating on Wynn Resorts (WYNN), Lowers Q2 Estimates
• General Mills (GIS) PT Raised to $33 at UBS, Sell Rating Maintained